ArticleJournal of the National Medical Association2006
Body mass index as a prognostic factor in endometrioid adenocarcinoma of the endometrium.
Article in Journal of the National Medical Association, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 4 syntheses or guidelines pooled it, 50 citations in OpenAlex.
- Diagnostic Accuracy of Clinical Biomarkers for Preoperative Prediction of Lymph Node Metastasis in Endometrial Carcinoma: A Systematic Review and Meta-Analysis.The oncologist · 2019Pooled it
- Body mass index and mortality in endometrial cancer: A systematic review and meta-analysis.Gynecologic oncology · 2016Pooled it
- Prognostic role of hormone receptors in endometrial cancer: a systematic review and meta-analysis.World journal of surgical oncology · 2015Pooled it
- Obesity and endometrial cancer survival: a systematic review.International journal of obesity (2005) · 2013Pooled it
- A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.Gynecologic oncology · 2013Trial
- The DNA Damage Response (DDR) landscape of endometrial cancer defines discrete disease subtypes and reveals therapeutic opportunities.NAR cancer · 2024Article
- Prognostic molecular biomarkers in endometrial cancer: A review.Journal of cancer research & therapy · 2019Article
- High visceral fat percentage is associated with poor outcome in endometrial cancer.Oncotarget · 2017Article
- Leptin receptor expression during the progression of endometrial carcinoma is correlated with estrogen and progesterone receptors.Archives of medical science : AMS · 2017Article
- Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trial.Gynecologic oncology · 2015Article
- Impact of body mass index on the prognosis of Korean women with endometrioid adenocarcinoma of the uterus: A cohort study.Obstetrics & gynecology science · 2014Article
- A new inflammation index is useful for patients with esophageal squamous cell carcinoma.OncoTargets and therapy · 2014Article
- Prediagnosis body mass index, physical activity, and mortality in endometrial cancer patients.Journal of the National Cancer Institute · 2013Article
- A high body mass index is not a worse prognostic factor for endometrial carcinoma in a predominantly obese population.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2013Article
- Body mass index, physical activity, and survival after endometrial cancer diagnosis: results from the Women's Health Initiative.Gynecologic oncology · 2013Article
- Adult granulosa cell tumor associated with endometrial carcinoma: a case report.Journal of medical case reports · 2011Article
- High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer.British journal of cancer · 2011Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine if body mass index (BMI) influences tumor expression of HER-2/neu, estrogen and progesterone receptors (ER/PR), and survival in women with endometrial adenocarcinoma.
methodsPatients diagnosed between January 1992 and December 2001 with endometrioid adenocarcinoma of the uterus were identified. Clinical and pathologic data were retrospectively collected. HER-2/neu, estrogen and progesterone receptor expression were determined by immunohistochemistry. Differences in these variables and other prognostic factors were analyzed and correlated with effect on survival.
resultsOne-hundred-sixty-five patients were included in this analysis. Lower BMI was associated with high stage (p=0.04) and HER-2/neu expression (p=0.04). Black race, high grade, high stage and lack of ER/PR expression were all associated with decreased survival. Despite having better prognostic factors, women with a BMI >25 had a lower survival than women with a BMI <25 (p=0.36). When five-year survival rates were calculated for BMI category and stratified by prognostic factors, for almost every high risk factor, survival was lower in overweight patients.
conclusionIn patients with endometrioid adenocarcinoma, low BMI is associated with high stage and tumor expression of HER-2/neu. Despite better prognostic factors, overweight women experience poorer survival.
Indexed as
Identifiers
17128692PMC2569783W114586477What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.